Management of Benign Hepatic Tumors

Surgical Clinics of North America

Volumn 90, Issue 4, 2010, Pages 719-735

  Buell, Joseph F ^a   Tranchart, Hadrien ^b   Cannon, Robert ^a   Dagher, Ibrahim ^b  

^a Tulane Center for Abdominal Transplantation   (United States)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Adenoma; Benign; Focal nodular hyperplasia; Hemangioma; Liver tumor

Indexed keywords

GADOLINIUM; GALLIUM 67; MANGAFODIPIR; ORAL CONTRACEPTIVE AGENT; SUPERPARAMAGNETIC IRON OXIDE; TAMOXIFEN; TECHNETIUM 99M; TECHNETIUM SULFUR COLLOID TC 99M;

ANGIOMYOLIPOMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; LAPAROSCOPIC SURGERY; LIVER ADENOMA; LIVER ADENOMATOSIS; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HEMANGIOMA; LIVER NODULAR REGENERATIVE HYPERPLASIA; LIVER RESECTION; LIVER SURGERY; LIVER TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS BIOPSY; PLASMA CELL GRANULOMA; PREGNANCY; PRIORITY JOURNAL; PSEUDOTUMOR; REVIEW; ADENOMA, LIVER CELL; DIFFERENTIAL DIAGNOSIS; FOCAL NODULAR HYPERPLASIA; HEMANGIOMA; INCIDENCE; LAPAROSCOPY; LIVER NEOPLASMS; PROCEDURES;

ADENOMA, LIVER CELL; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; FOCAL NODULAR HYPERPLASIA; HEMANGIOMA; HEPATECTOMY; HUMANS; INCIDENCE; LAPAROSCOPY; LIVER NEOPLASMS;

EID: 77954631923     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2010.04.006     Document Type: Review

References (101)

1. Foster J.H. Survival after liver resection for cancer. Cancer 1970, 26(3):493-502.
2. Shiu M.H., Fortner J.G. Current management of hepatic tumors. Surg Gynecol Obstet 1975, 140(5):781-788.
3. Fortner J.G., Shiu M.H., Kinne D.W., et al. Major hepatic resection using vascular isolation and hypothermic perfusion. Ann Surg 1974, 180(4):644-652.
4. Almersjö O., Bengmark S., Hafström L. Liver resection for cancer. Acta Chir Scand 1976, 142(2):139-144.
5. Schiff L. Hepatic neoplasia: selected clinical aspects. Semin Roentgenol 1983, 18(2):71-74.
6. Ishak K.G., Rabin L. Benign tumors of the liver. Med Clin North Am 1975, 59(4):995-1013.
7. Takagi H. Diagnosis and management of cavernous hemangioma of the liver. Semin Surg Oncol 1985, 1(1):12-22.
8. Lencioni R., Crocetti L., Della Pina M.C., et al. Guidelines for imaging focal lesions in liver cirrhosis. Expert Rev Gastroenterol Hepatol 2008, 2(5):697-703.
9. Yu J.S., Chung J.J., Kim J.H., et al. Large (>or=2 cm) non-hypervascular nodules depicted on MRI in the cirrhotic liver: fate and implications. Clin Radiol 2008, 63(10):1121-1130.
10. Sun H.Y., Lee J.M., Shin C.I., et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (
11. Macarini L., Milillo P., Cascavilla A., et al. MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers. Radiol Med 2009, 114(8):1267-1282.
12. Yu J.S., Chung J.J., Kim J.H., et al. Hypervascular focus in the nonhypervascular nodule (" nodule-in-nodule" ) on dynamic computed tomography: imaging evidence of aggressive progression in hepatocellular carcinoma. J Comput Assist Tomogr 2009, 33(1):131-135.
13. Vandecaveye V., De Keyzer F., Verslype C., et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 2009, 19(10):2456-2466.
14. Mentha G., Rubbia-Brandt L., Howarth N., et al. Management of focal nodular hyperplasia and hepatocellular adenoma. Swiss Surg 1999, 5(3):122-125.
15. De Carlis L., Pirotta V., Rondinara G.F., et al. Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg 1997, 3(2):160-165.
16. Choi B.Y., Nguyen M.H. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005, 39(5):401-412.
17. Ardito F., Tayar C., Laurent A., et al. Laparoscopic liver resection for benign disease. Arch Surg 2007, 142(12):1188-1193.
18. Dagher I., Di Giuro G., Lainas P., et al. Laparoscopic right hepatectomy with selective vascular exclusion. J Gastrointest Surg 2009, 13(1):148-149.
19. Buell J.F., Cherqui D., Geller D.A., et al. World Consensus Conference on Laparoscopic Surgery. The international position on laparoscopic liver surgery: the Louisville Statement, 2008. Ann Surg 2009, 250(5):825-830.
20. Vibert E., Kouider A., Gayet B. Laparoscopic anatomic liver resection. HPB (Oxford) 2004, 6(4):222-229.
21. Gigot J.F., Hubert C., Banice R., et al. Laparoscopic management of benign liver diseases: where are we?. HPB (Oxford) 2004, 6(4):197-212.
22. Assy N., Nasser G., Djibre A., et al. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol 2009, 15(26):3217-3227.
23. Bolondi L., Gaiani S., Celli N., et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005, 42(1):27-34.
24. Jang H.J., Yu H., Kim T.K. Imaging of focal liver lesions. Semin Roentgenol 2009, 44(4):266-282.
25. Noda I., Kitamoto M., Nakahara H., et al. Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2010, 45(1):105-112.
26. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Suppl 1):S20-S37.
27. Zuber-Jerger I., Schacherer D., Woenckhaus M., et al. Contrast-enhanced ultrasound in diagnosing liver malignancy. Clin Hemorheol Microcirc 2009, 43(1):109-118.
28. Seitz K., Strobel D., Bernatik T., et al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Ultraschall Med 2009, 30(4):383-389.
29. Lencioni R., Piscaglia F., Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008, 48(5):848-857.
30. Jang H.J., Yu H., Kim T.K. Contrast-enhanced ultrasound in the detection and characterization of liver tumors. Cancer Imaging 2009, 6(9):96-103.
31. Goyal N., Jain N., Rachapalli V., et al. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol 2009, 64(11):1056-1066.
32. Yoon S.H., Lee J.M., So Y.H., et al. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 2009, 193(6):W482-W489.
33. Zacherl J., Pokieser P., Wrba F., et al. Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth?. Ann Surg 2002, 235(4):528-532.
34. Peterson M.S., Baron R.L., Marsh J.W., et al. Pretransplantation surveillance for possible hepatocellular carcinoma in patients with cirrhosis: epidemiology and CT-based tumor detection rate in 430 cases with surgical pathologic correlation. Radiology 2000, 217(3):743-749.
35. Catalano O., Cusati B., Sandomenico F., et al. Multiple-phase spiral computerized tomography of small hepatocellular carcinoma: technique optimization and diagnostic yield. Radiol Med 1999, 98(1-2):53-64.
36. Yoo H.J., Lee J.M., Lee J.Y., et al. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol 2009.
37. Burrel M., Llovet J.M., Ayuso C., et al. Barcelona Clínic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003, 38(4):1034-1042.
38. Catalano O.A., Choy G., Zhu A., et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010, 254(1):154-162.
39. Goshima S., Kanematsu M., Matsuo M., et al. Malignant hepatic tumor detection with ferumoxide-enhanced magnetic resonance imaging: is chemical-shift-selective fat suppression necessary for fast spin-echo sequence?. J Magn Reson Imaging 2004, 20(1):75-82.
40. Kato H., Kanematsu M., Kondo H., et al. Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity. J Magn Reson Imaging 2004, 19(1):76-81.
41. Huynh L.T., Kim S.Y., Murphy T.F. The typical appearance of focal nodular hyperplasia in triple-phase CT scan, hepatobiliary scan, and Tc-99m sulfur colloid scan with SPECT. Clin Nucl Med 2005, 30(11):736-739.
42. Weigand K., Weigand K. Percutaneous liver biopsy: retrospective study over 15 years comparing 287 inpatients with 428 outpatients. J Gastroenterol Hepatol 2009, 24(5):792-799.
43. Padia S.A., Baker M.E., Schaeffer C.J., et al. Safety and efficacy of sonographic-guided random real-time core needle biopsy of the liver. J Clin Ultrasound 2009, 37(3):138-143.
44. Cook J.A., Harrison S.A. Same day endoscopy and percutaneous liver biopsy: safety and cost-effectiveness. Dig Dis Sci 2009, 54(8):1753-1757.
45. Reddy K.R., Kligerman S., Levi J., et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001, 67(2):173-178.
46. Mergo P.J., Ros P.R. Benign lesions of the liver. Radiol Clin North Am 1998, 36(2):319-331.
47. Trotter J.F., Everson G.T. Benign focal lesions of the liver. Clin Liver Dis 2001, 5(1):17-42.
48. Motohara T., Semelka R.C., Nagase L. MR imaging of benign hepatic tumors. Magn Reson Imaging Clin N Am 2002, 10(1):1-14.
49. Mortele K.J., Ros P.R. Benign liver neoplasms. Clin Liver Dis 2002, 6(1):119-145.
50. Semelka R.C., Martin D.R., Balci C., et al. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001, 13(3):397-401.
51. Namimoto T., Yamashita Y., Sumi S., et al. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997, 204(3):739-744.
52. Pain J.A., Gimson A.E., Williams R., et al. Focal nodular hyperplasia of the liver: results of treatment and options in management. Gut 1991, 32(5):524-527.
53. Sadowski D.C., Lee S.S., Wanless I.R., et al. Progressive type of focal nodular hyperplasia characterized by multiple tumors and recurrence. Hepatology 1995, 21(4):970-975.
54. Wanless I.R., Mawdsley C., Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985, 5(6):1194-1200.
55. Gaffey M.J., Iezzoni J.C., Weiss L.M. Clonal analysis of focal nodular hyperplasia of the liver. Am J Pathol 1996, 148(4):1089-1096.
56. Nguyen B.N., Flejou J.F., Terris B., et al. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999, 23(12):1441-1454.
57. Terkivatan T., de Wilt J.H., de Man R.A., et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001, 136(9):1033-1038.
58. Kim T.K., Jang H.J., Burns P.N., et al. Focal nodular hyperplasia and hepatic adenoma: differentiation with low-mechanical-index contrast-enhanced sonography. AJR Am J Roentgenol 2008, 190(1):58-66.
59. Terkivatan T., van den Bos I.C., Hussain S.M., et al. Focal nodular hyperplasia: lesion characteristics on state-of-the-art MRI including dynamic gadolinium-enhanced and superparamagnetic iron-oxide-uptake sequences in a prospective study. J Magn Reson Imaging 2006, 24(4):864-872.
60. Grazioli L., Morana G., Kirchin M.A., et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005, 236(1):166-177.
61. Edmondson H.A., Henderson B., Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976, 294(9):470-472.
62. Rooks J.B., Ory H.W., Ishak K.G., et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979, 242(7):644-648.
63. Heinemann L.A., Weimann A., Gerken G., et al. Modern oral contraceptive use and benign liver tumors: the German benign liver tumor case-control study. Eur J Contracept Reprod Health Care 1998, 3(4):194-200.
64. Bagia S., Hewitt P.M., Morris D.L. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder. Aust N Z J Surg 2000, 70(9):686-687.
65. Dokmak S., Paradis V., Vilgrain V., et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009, 137(5):1698-1705.
66. Di Stasi M., Caturelli E., De Sio I., et al. Natural history of focal nodular hyperplasia of the liver: an ultrasound study. J Clin Ultrasound 1996, 24(7):345-350.
67. Terkivatan T., de Wilt J.H., de Man R.A., et al. Treatment of ruptured hepatocellular adenoma. Br J Surg 2001, 88(2):207-209.
68. Ruppert-Kohlmayr A.J., Uggowitzer M.M., Kugler C., et al. Focal nodular hyperplasia and hepatocellular adenoma of the liver: differentiation with multiphasic helical CT. AJR Am J Roentgenol 2001, 176(6):1493-1498.
69. Krasinskas A. The significance of nodular regenerative hyperplasia in the transplanted liver. Liver Transpl 2007, 13(11):1496-1497.
70. Krasinskas A.M., Eghtesad B., Kamath P.S., et al. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005, 11(6):627-634. [discussion: 610-1].
71. Mathieu D., Vasile N., Menu Y., et al. Budd-Chiari syndrome: dynamic CT. Radiology 1987, 165(2):409-413.
72. Miller W.J., Federle M.P., Straub W.H., et al. Budd-Chiari syndrome: imaging with pathologic correlation. Abdom Imaging 1993, 18(4):329-335.
73. Grazioli L., Alberti D., Olivetti L., et al. Congenital absence of portal vein with nodular regenerative hyperplasia of the liver. Eur Radiol 2000, 10(5):820-825.
74. Menon K.V., Shah V., Kamath P.S. The Budd-Chiari syndrome. N Engl J Med 2004, 350(6):578-585.
75. Vilgrain V., Lewin M., Vons C., et al. Hepatic nodules in Budd-Chiari syndrome: imaging features. Radiology 1999, 210(2):443-450.
76. Nonomura A., Mizukami Y., Kadoya M. Angiomyolipoma of the liver: a collective review. J Gastroenterol 1994, 29(1):95-105.
77. Ahmadi T., Itai Y., Takahashi M., et al. Angiomyolipoma of the liver: significance of CT and MR dynamic study. Abdom Imaging 1998, 23(5):520-526.
78. Sawai H., Manabe T., Yamanaka Y., et al. Angiomyolipoma of the liver: case report and collective review of cases diagnosed from fine needle aspiration biopsy specimens. J Hepatobiliary Pancreat Surg 1998, 5(3):333-338.
79. Rouquie D., Eggenspieler P., Algayres J.P., et al. Ann Chir 2006, 131(5):338-341. [in French].
80. Parfitt J.R., Bella A.J., Izawa J.I., et al. Malignant neoplasm of perivascular epithelioid cells of the liver. Arch Pathol Lab Med 2006, 130(8):1219-1222.
81. Dalle I., Sciot R., de Vos R., et al. Malignant angiomyolipoma of the liver: a hitherto unreported variant. Histopathology 2000, 36(5):443-450.
82. Cessna M.H., Zhou H., Sanger W.G., et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 2002, 15(9):931-938.
83. Caramella T., Novellas S., Fournol M., et al. J Radiol 2007, 88(6):882-888. [in French].
84. Liu G.J., Lu M.D., Xie X.Y., et al. Real-time contrast-enhanced ultrasound imaging of infected focal liver lesions. J Ultrasound Med 2008, 27(4):657-666.
85. Wang W.P., Ding H., Qi Q., et al. Characterization of focal hepatic lesions with contrast-enhanced C-cube gray scale ultrasonography. World J Gastroenterol 2003, 9(8):1667-1674.
86. Materne R., Van Beers B.E., Gigot J.F., et al. Inflammatory pseudotumor of the liver: MRI with mangafodipir trisodium. J Comput Assist Tomogr 1998, 22(1):82-84.
87. Horiuchi R., Uchida T., Kojima T., et al. Inflammatory pseudotumor of the liver. Clinicopathologic study and review of the literature. Cancer 1990, 65(7):1583-1590.
88. Hagenstad C.T., Kilpatrick S.E., Pettenati M.J., et al. Inflammatory myofibroblastic tumor with bone marrow involvement. A case report and review of the literature. Arch Pathol Lab Med 2003, 127(7):865-867.
89. Zavaglia C., Barberis M., Gelosa F., et al. Inflammatory pseudotumour of the liver with malignant transformation. Report of two cases. Ital J Gastroenterol 1996, 28(3):152-159.
90. Giannitrapani L., Soresi M., La Spada E., et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci 2006, 1089:228-236.
91. Dourakis S.P., Tolis G. Sex hormone preparations and the liver. Eur J Contracept Reprod Health Care 1998, 3(1):7-16.
92. Lindberg M.C. Hepatobiliary complication of oral contraceptives. J Gen Intern Med 1992, 7(2):199-209.
93. Nagasue N., Kohno H. Hepatocellular carcinoma and sex hormones. HPB Surg 1992, 6(1):1-6.
94. Scalori A., Tayani A., Gallus S., et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case control study. Am J Obstet Gynecol 2002, 186(2):195-197.
95. Mathieu D., Kobeiter H., Maison P., et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000, 118(3):560-564.
96. Baum J.K., Bookstein J.J., Holtz F., et al. Possible association between benign hepatomas and oral contraceptives. Lancet 1973, 2(7835):926-929.
97. Lee N.M., Brady C.W. Liver disease in pregnancy. World J Gastroenterol 2009, 15(8):897-906.
98. Haram K., Svendsen E., Abildgaard U. The HEELP syndrome: clinical issues and management. BMC Pregnancy Childbirth 2009, 9:8.
99. Kulungowski A.M., Kashuk J.L., Moore E.E., et al. HEELP syndrome: when is surgical help needed?. Am J Surg 2009, 198(6):916-920.
100. Micchelli S.T., Vivekanandan P., Boitnott J.K., et al. Malignant transformation of hepatic adenomas. Mod Pathol 2008, 21(4):491-497.
101. van der Windt D.J., Kok N.F., Hussain S.M., et al. Case oriented approach to the management of hepatocellular adenoma. Br J Surg 2006, 93(12):1495-1502.